Aviva’s Utah Medical Products UTMD Stock Holding History

Aviva’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,266	Closed	-$219K	–	901
2024 Q3	$219K	Buy	3,266 +206	+7%	+$14K	﹤0.01%	868
2024 Q2	$204K	Buy	+3,060	New	+$208K	﹤0.01%	904

Other funds holding UTMD

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Aviva's UTMD Position: Q4 2024 in Review

Aviva sold out of Utah Medical Products (UTMD) in Q4 2024, closing a stake of 3,266 shares — an estimated $219K sold.

Aviva first reported a position in UTMD in Q2 2024 and held it in 2 quarters. The position peaked at $219K in Q3 2024. 112 funds tracked by Wall St. Rank hold UTMD as of Q4 2024.

Aviva reported no remaining Utah Medical Products position as of Q4 2024 after selling out during the quarter.
Aviva sold 3,266 Utah Medical Products shares in Q4 2024, an estimated $219K.
Aviva first reported a position in Utah Medical Products in Q2 2024 and held it in 2 quarters.
Aviva's Utah Medical Products position peaked at $219K in Q3 2024.
112 funds tracked by Wall St. Rank held Utah Medical Products as of Q4 2024.

Based on Aviva's 13F filing for Q4 2024, filed 13 Feb 2025.